A potential biomarker for bipolar i disorder: Serum arginine vasopressin levels;Bipolar I bozukluğu için potansiyel bir biyomarker: Serum arjinin vasopressin düzeyleri

Anadolu Psikiyatri Dergisi

Volumn 18, Issue 3, 2017, Pages 195-202

  Asdemir, Akif ^a   Turan, Tayfun ^b   Uysal, Cengiz ^c   Kiliç, Eser ^d  

^a Psychiatrist   (Turkey)

^b Department of Psychiatry ^*  (Turkey)

^c AHI EVRAN UNIVERSITY   (Turkey)

^d ERCIYES UNIVERSITY MEDICAL FACULTY   (Turkey)

Author keywords

Arginine vasopressin; Bipolar I disorder; Bipolar remission; Depressive episode; Manic episode; Treatment response

Indexed keywords

ARGIPRESSIN; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; BIOLOGICAL MARKER; MOOD STABILIZER; NEUROLEPTIC AGENT; TETRACYCLIC ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; BIPOLAR I DISORDER; BLOOD CHEMISTRY; BLOOD SAMPLING; BODY MASS; CONTROLLED STUDY; DEMOGRAPHY; DEPRESSION; DSM-IV-TR; FEMALE; HAMILTON DEPRESSION RATING SCALE; HUMAN; INTERVIEW; KIDNEY FUNCTION TEST; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MANIA; NEUROLOGIC EXAMINATION; PHYSICAL EXAMINATION; REMISSION; SMOKING; THYROID FUNCTION TEST; VASOPRESSIN BLOOD LEVEL; YOUNG MANIA RATING SCALE;

EID: 85020786517     PISSN: 13026631     EISSN: None     Source Type: Journal    
DOI: 10.5455/apd.224253     Document Type: Article

References (28)

1. Benarroch EE. Oxytocin and vasopressin: social neuropeptides with complex neuromodulatory functions. Neurology 2013; 80:1521-1528.
2. Koshimizu T, Nakamura K, Egashira N, Hiroyama M, Nonoguchi H, Tanoue A. Vasopressin V1a and V1b receptors: from molecules to physiological systems. Physiol Rev 2012; 92:1813-1864.
3. Caldwell HK, Lee HJ, Macbeth AH, Young, WS, 3rd. Vasopressin: behavioral roles of an “original” neuropeptide. Prog Neurobiol 2008; 84:1-24.
4. Frank E, Landgraf R. The vasopressin system-from antidiuresis to psychopathology. Eur J Pharmacol 2008; 583:226-242.
5. Rubin LH, Carter CS, Bishop JR, Pournajafi-Nazarloo H, Drogos LL, Hill SK, et al. Reduced levels of vasopressin and reduced behavioral modulation of oxytocin in psychotic disorders. Schizophr Bull 2014; 40:1374-1384.
6. Zelena D. Vasopressin in health and disease with a focus on affective disorders. Cent Nerv Syst Agents Med Chem 2012; 12:286-303.
7. Stanley B, Siever LJ. The Interpersonal Dimension of Borderline Personality Disorder: Toward a Neuropeptide Model. Am J Psychiatry 2010; 167:24-39.
8. de Kloet CS, Vermetten E, Geuze E, Wiegant VM, Westenberg HG. Elevated plasma arginine vasopressin levels in veterans with posttraumatic stress disorder. J Psychiatr Res 2008; 42:192-198.
9. Task Force on DSM-IV. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. Fourth ed., Washington, DC: American Psychiatric Association, 2000.
10. Murri MB, Prestia D, Mondelli V, Pariante C, Patti S, Olivieri B, et al. The HPA axis in bipolar disorder: Systematic review and meta-analysis. Psychoneuroendocrinology 2016; 63:327-342.
11. Gold PW, Goodwin FK, Reus VI. Vasopressin in affective illness. Lancet 1978; 1:1233-1236.
12. Sorensen PS, Gjerris A, Hammer M. Cerebro-spinal fluid vasopressin in neurological and psychiatric disorders. J Neurol Neurosurg Psychiatry 1985; 48:50-57.
13. Legros JJ, Ansseau M. Increased basal plasma vasopressin-neurophysin in mania. Horm Res 1989; 31:55-58.
14. Linkowski P, Geenen V, Kerkhofs M, Mendlewicz J, Legros JJ. Cerebrospinal fluid neurophysins in affective illness and in schizophrenia. Eur Arch Psychiatry Neurol Sci 1984; 234:162-165.
15. Berrettini WH, Nurnberger JI Jr, Zerbe RL, Gold PW, Chrousos GP, Tomai T. CSF neuropeptides in euthymic bipolar patients and controls. Br J Psychiatry 1987; 150:208-212.
16. Gjerris A, Hammer M, Vendsborg P, Christensen NJ, Rafaelsen OJ. Cerebrospinal fluid vaso-pressin-changes in depression. Br J Psychiatry 1985; 147:696-701.
17. Penney MD, Levell MJ, Hullin RP. Arginine vasopressin in manic-depressive psychosis. Psychol Med 1987; 17:861-867.
18. Kagerbauer SM, Martin J, Schuster T, Blobner M, Kochs EF, Landgraf R. Plasma oxytocin and vasopressin do not predict neuropeptide concentrations in human cerebrospinal fluid. J Neuroendocrinol 2013; 25:668-673.
19. Carson DS, Howerton CL, Garner JP, Hyde SA, Clark CL, Hardan AY, et al. Plasma vasopressin concentrations positively predict cerebrospinal fluid vasopressin concentrations in human neo-nates. Peptides 2014; 61:12-16.
20. Turan T, Uysal C, Asdemir A, Kılıç E. May oxytocin be a trait marker for bipolar disorder? Psychoneuroendocrinology 2013; 38:2890-2896.
21. Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2013; 310:2191-2194.
22. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978; 133:429-435.
23. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56-61.
24. Tang V, Wang J. Oxidative Stress in Bipolar Disorder. Biochem Anal Biochem 2012; S2-002. doi:10.4172/2161-1009.S2-002.
25. Bielau H, Trübner K, Krell D, Agelink MW, Bernstein H, Stauch R, et al. Volume deficits of subcortical nuclei in mood disorders. Eur Arch Psychiatry Clin Neurosci 2005; 255:401-412.
26. Schindler S, Geyer S, Strauss M, Anwander A, Hegerl U, Turner R, et al. Structural studies of the hypothalamus and its nuclei in mood disorders. Psychiatry Res 2012; 201:1-9.
27. Grande I, Berk M, Birmaher B, Vieta E. Bipolar disorder. Lancet; www.thelancet.com Published online September 18, 2015; http://dx.doi.org/10.1016/S0140-6736(15)00241-X
28. Phillips ML, Kupfer DJ. Bipolar disorder diagnosis: Challenges and future directions. Lancet 2013; 381:1663-1671.